Clinical Trial Update: Afatinib in EGFR+NSCLC (Recurrent or Stage IV) - Patients With Poor Performance Status (ECOG 2 or 3) [Phase 4]

View source ↗

Summary

Phase 4 trial update for afatinib in EGFR-positive non-small cell lung cancer patients with poor performance status has been terminated; results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Carcinoma

Drugs mentioned

• Afatinib (afatinib)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Carcinoma, Non-Small-Cell Lung, ErbB Receptors | Phase 4 | Status: TERMINATED | Results posted: 2017-09-18